진드기 매개 뇌염 불활화 백신 시장 규모 : 바이러스 유형별, 최종 사용자별, 지역 범위별 예측

Tick-Borne Encephalitis Inactivated Vaccine Market Size And Forecast

Tick-Borne Encephalitis Inactivated Vaccine Market size was valued at USD 300 Million in 2024 and is projected to reach USD 480 Million by 2032, growing at a CAGR of 7.2% during the forecast period 2026-2032.

Global Tick-Borne Encephalitis Inactivated Vaccine Market Drivers

The market drivers for the Tick-Borne Encephalitis Inactivated Vaccine Market can be influenced by various factors. These may include:

Prevalence and Incidence: The demand for vaccinations can be strongly influenced by the prevalence and incidence of TBE in areas where it is endemic or emerging. Increasing incidence rates frequently prompts more immunization campaigns.

Awareness and Education: Vaccination demand may be influenced by public awareness campaigns and educational programs highlighting the dangers of TBE. People may seek vaccinations for themselves and their families as they become more aware of the illness and its possible effects.

Immunization Programs and Government Policies: Including TBE vaccines in national immunization programs or enforcing vaccination laws can have a significant impact on consumer demand. Reimbursements or subsidies for the cost of vaccinations might also encourage uptake.

Travel and Tourism Trends: Travel-related business travel (TBE) is common in several areas, especially in portions of Europe and Asia. Travelers seeking protection against the disease may find a greater need for TBE vaccinations as a result of increased travel and tourism to these regions.

Research and Development: By boosting vaccination confidence and reaching a wider audience, developments in vaccine technology, such as those that enhance safety, efficacy, and convenience of administration, can propel market expansion.

Outbreaks and Epidemics: When TBE occurs, there may be a surge in public anxiety and a need for vaccinations as people try to vaccinate against the illness.

Climate Change and Ecological Factors: TBE-carrying tick distribution and prevalence can be altered by changes in climate and ecological factors. This could lead to an expansion of the disease's geographic range and a greater requirement for immunization in previously unaffected areas.

Healthcare Infrastructure: Vaccination rates and market demand may be impacted by the accessibility and availability of healthcare infrastructure, such as vaccination clinics and medical personnel qualified to give TBE vaccines.

Insurance Coverage: A TBE vaccination's insurance coverage and reimbursement policies may have an impact on accessibility and affordability, which in turn may have an effect on market demand.

Global Tick-Borne Encephalitis Inactivated Vaccine Market Restraints

Several factors can act as restraints or challenges for the Tick-Borne Encephalitis Inactivated Vaccine Market. These may include:

Limited Education and Awareness: The general public's ignorance about tick-borne illnesses and the accessibility of vaccines can impede the expansion of the industry. There might not be as much demand for the vaccine in areas where TBE is uncommon because of a lack of knowledge about the hazards.

Geographic Restrictions: TBE is mostly endemic in some parts of Asia and Europe. The demand for the vaccine may be restricted in regions with low incidence of TBE, which could hinder efforts to expand the market.

Economic Factors: Access to vaccines may be hampered by financial limitations, especially in low-income nations. Adoption may be hampered by the expense of immunization campaigns and the vaccine itself, particularly in areas with little access to healthcare.

Regulatory Obstacles: Tight regulations pertaining to vaccination distribution and approval may impede market expansion. For vaccine producers, obtaining regulatory clearances in many nations and areas can be expensive and time-consuming.

Vaccine reluctance: Misinformation and worries about the effectiveness and safety of vaccines can all lead to vaccination reluctance. This may have an effect on TBE vaccination uptake and impede market expansion.

Competition from Other Preventive Measures: The adoption of vaccines may face competition from other preventive measures like wearing protective clothing and using insect repellents. Furthermore, rival vaccinations or different methods of preventing TBE could restrict market expansion.

Seasonality: When tick activity is at its highest, TBE incidence frequently rises during specific seasons. The market demand for vaccinations may fluctuate throughout the year as a result of this seasonality.

Supply Chain Difficulties: Vaccine manufacture, delivery, and storage can be complicated, which might present problems for market participants. It might be challenging to keep a steady supply chain when TBE is common, particularly in isolated or resource-constrained places.

Global Tick-Borne Encephalitis Inactivated Vaccine Market Segmentation Analysis

The Global Tick-Borne Encephalitis Inactivated Vaccine Market is segmented on the basis of Virus Type, End User, And Geography.

Tick-Borne Encephalitis Inactivated Vaccine Market, By Virus Type

• Siberian TBE Virus
• Far Eastern TBE Virus
• European TBE Virus

Based on Virus Type, The market is segmented into Siberian TBE Virus, Far Eastern TBE Virus, and European TBE Virus. The three types of TBEV are TBEV-European, TBEV-Siberian, and TBEV-Far Eastern (previously Russian spring-summer encephalitis virus), which differ in geography and disease presentation. TBEV usually causes febrile disease, which may be followed by severe neurological disorders, such as encephalitis and meningitis. Some virus strains, like TBEV-Far Eastern, have a high mortality rate, and many survivors suffer from long-term sequelae.

Tick-Borne Encephalitis Inactivated Vaccine Market, By End User

• Traveler Vaccines
• Pediatric Vaccines
• Adult Vaccines

Based on End User, The market is segmented into Traveler Vaccines, Pediatric Vaccines and Adult Vaccines. Travelers who anticipate high-risk exposures, such as working or camping in forested regions or farmland, adventurous travel, or long stays in TBE-endemic nations.

Tick-Borne Encephalitis Inactivated Vaccine Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world
• On the basis of Regional Analysis, The Global Tick-Borne Encephalitis Inactivated Vaccine Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. TBE is endemic in a few areas in Europe and Asia, ranging from eastern France to northern Japan, and from northern Russia to Albania. The country with the most reported cases is Russia. Western Siberia, Slovenia, and the Baltic States have recorded the highest disease incidence.

Key Players

• The major players in the Tick-Borne Encephalitis Inactivated Vaccine Market are:
• GlaxoSmithKline plc.
• London Travel Clinic
• Superdrug Health Clinic
• Pfizer Inc.
• Encephalitis Global Inc.
• The Cochrane Collaboration
• Sonic HealthPlus Pty Ltd.
• Merck & Co. Inc.
• Baxter International Inc.
• Hawaii Biotech Inc.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL TICK-BORNE ENCEPHALITIS INACTIVATED VACCINE MARKET

• 1.1 Introduction of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL TICK-BORNE ENCEPHALITIS INACTIVATED VACCINE MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL TICK-BORNE ENCEPHALITIS INACTIVATED VACCINE MARKET, BY VIRUS TYPE

• 5.1 Overview
• 5.2 Siberian TBE Virus
• 5.3 Far Eastern TBE Virus
• 5.4 European TBE Virus

6 GLOBAL TICK-BORNE ENCEPHALITIS INACTIVATED VACCINE MARKET, END USER

• 6.1 Overview
• 6.2 Traveler Vaccines
• 6.3 Pediatric Vaccines
• 6.4 Adult Vaccines

7 GLOBAL TICK-BORNE ENCEPHALITIS INACTIVATED VACCINE MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East and Africa

8 GLOBAL TICK-BORNE ENCEPHALITIS INACTIVATED VACCINE MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 GlaxoSmithKline plc.
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 London Travel Clinic
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Superdrug Health Clinic
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Pfizer Inc.
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Encephalitis Global, Inc
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 The Cochrane Collaboration
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 Sonic HealthPlus Pty Ltd
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 Merck & Co., Inc
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 Baxter International Inc
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments
• 9.10 Hawaii Biotech, Inc
  • 9.10.1 Overview
  • 9.10.2 Financial Performance
  • 9.10.3 Product Outlook
  • 9.10.4 Key Developments

10 KEY DEVELOPMENTS

• 10.1 Product Launches/Developments
• 10.2 Mergers and Acquisitions
• 10.3 Business Expansions
• 10.4 Partnerships and Collaborations

11 Appendix

• 11.1 Related Research